To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Clinical value of tranexamic acid for blood loss in unilateral and bilateral TKAs

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Author Verified
Ace Report Cover
October 2014

Clinical value of tranexamic acid for blood loss in unilateral and bilateral TKAs

Vol: 3| Issue: 10| Number:29| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Clinical value of tranexamic acid in unilateral and simultaneous bilateral TKAs under a contemporary blood-saving protocol: a randomized controlled trial

Knee Surg Sports Traumatol Arthrosc. 2014 Aug;22(8):1870-8

Contributing Authors:
TK Kim CB Chang YG Kang ES Seo JH Lee JH Yun SH Lee

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

180 unilateral and 150 bilateral total knee arthroplasty (TKA) patients were randomly allocated into either a tranexamic acid (TXA) group or a control group. There were similar trends found in both unilateral and bilateral TKA groups treated with TXA, in regards to reducing total blood loss, blood loss via the drain, and haemoglobin drop. However, only TXA patients that had undergone bilateral TKA...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue